Novartis Immuno-oncology Drug Candidate Fails Skin Cancer Trial

Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immunooncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a latestage trial for a type of advanced skin cancer.

from Top Business News- News18.com https://ift.tt/31lzcBn
via IFTTT